What is Digostics?
Digostics operates at the intersection of medical technology and patient-centric healthcare, specializing in innovative home-testing platforms for diabetes management. The company's flagship solution focuses on the oral glucose tolerance test (OGTT), a critical diagnostic procedure that has historically required in-clinic attendance. By enabling lab-quality accuracy within a home environment, Digostics effectively removes barriers to early detection and screening for type 1, type 2, and gestational diabetes. Their platform is engineered for interoperability, ensuring that clinical researchers and healthcare providers can seamlessly integrate patient data into existing care pathways, thereby facilitating more timely and effective clinical interventions.
The company's market position is defined by its commitment to reducing the logistical burden on patients while maintaining the rigorous standards required by medical professionals. By digitizing and decentralizing the OGTT process, Digostics addresses a significant gap in the chronic disease management market, providing a scalable solution that supports both individual health outcomes and broader public health initiatives.
How much funding has Digostics raised?
Digostics has raised a total of $675K across 1 funding round:
Other Financing Round
$675K
Other Financing Round (2025): $675K, investors not publicly disclosed
Key Investors in Digostics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Digostics?
With this major strategic investment, Digostics is poised to transition from a specialized diagnostic developer to a broader enterprise-level healthcare partner. The capital will likely be deployed to expand the company's operational footprint, enhance its digital interoperability features, and scale its manufacturing capabilities to meet growing demand from clinical research organizations and healthcare providers. As the firm continues to refine its diagnostic accuracy and user experience, the focus will shift toward securing broader regulatory approvals and establishing strategic partnerships with major health systems. This growth phase is critical for cementing Digostics' role as a leader in the decentralized diagnostics sector, ultimately aiming to transform the standard of care for diabetes screening on a global scale.
See full Digostics company page
